Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Post-Marketing Surveillance of Symbenda Injection (Bendamustine Hydrochloride) in Korean Patients

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02434484
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:51.009958+00:00
Published At
2021-01-26T00:00:00+00:00
Record Updated At
2021-01-26
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Lymphoma, Non-Hodgkin", "Lymphocytic Leukemia", "Multiple Myeloma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-01-26"
protocolSection.identificationModule.nctId
"NCT02434484"
protocolSection.identificationModule.officialTitle
"Post-Marketing Surveillance of Symbenda Injection (Bendamustine Hydrochloride) in Korean Patients"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Lymphoma, Non-Hodgkin (protocolSection.conditionsModule.conditions)
  • Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Multiple Myeloma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.